Terms: = Ovarian cancer AND MUTYH, MYH, 4595, ENSG00000132781, hMYH, MGC4416, MYHbeta
54 results:
1. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and ovarian cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract] [Full Text] [Related]
2. Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure.
Nolan J; Buchanan J; Taylor J; Almeida J; Bedenham T; Blair E; Broadgate S; Butler S; Cazeaux A; Craft J; Cranston T; Crawford G; Forrest J; Gabriel J; George E; Gillen D; Haeger A; Hastings Ward J; Hawkes L; Hodgkiss C; Hoffman J; Jones A; Karpe F; Kasperaviciute D; Kovacs E; Leigh S; Limb E; Lloyd-Jani A; Lopez J; Lucassen A; McFarlane C; O'Rourke AW; Pond E; Sherman C; Stewart H; Thomas E; Thomas S; Thomas T; Thomson K; Wakelin H; Walker S; Watson M; Williams E; Ormondroyd E
Genet Med; 2024 Mar; 26(3):101051. PubMed ID: 38131308
[TBL] [Abstract] [Full Text] [Related]
3. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
4. DNA Repair Pathway in ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
5. High-grade serous ovarian carcinoma with a sertoliform pattern associated with BRCA mutation: a clinicopathological and molecular analysis.
Travaglino A; Santoro A; Arciuolo D; Raffone A; Scaglione G; D'Alessandris N; Valente M; Sfregola S; Fulgione C; Onori ME; Minucci A; Zannoni GF
Virchows Arch; 2023 Dec; 483(6):879-883. PubMed ID: 37166561
[TBL] [Abstract] [Full Text] [Related]
6. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
7. Corded and hyalinized endometrioid endometrial carcinoma with high-grade features: a clinicopathological and TCGA-based molecular analysis.
Travaglino A; Arciuolo D; Santoro A; Raffone A; Pedone Anchora L; Piermattei A; Martinelli M; Mollo A; Onori ME; Minucci A; Inzani F; Fanfani F; Insabato L; Zannoni GF
Virchows Arch; 2023 Apr; 482(4):671-678. PubMed ID: 36550216
[TBL] [Abstract] [Full Text] [Related]
8. Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
Macklin-Mantia SK; Clift KE; Maimone S; Hodge DO; Riegert-Johnson D; Hines SL
J Genet Couns; 2023 Jun; 32(3):598-606. PubMed ID: 36478495
[TBL] [Abstract] [Full Text] [Related]
9. Increased Risk of Hereditary Prostate cancer in Italian Families with Hereditary Breast and ovarian cancer Syndrome Harboring Mutations in
D'Elia G; Caliendo G; Tzioni MM; Albanese L; Passariello L; Molinari AM; Vietri MT
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292577
[TBL] [Abstract] [Full Text] [Related]
10. Familial and hereditary gastric cancer, an overview.
Carneiro F
Best Pract Res Clin Gastroenterol; 2022; 58-59():101800. PubMed ID: 35988963
[TBL] [Abstract] [Full Text] [Related]
11. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract] [Full Text] [Related]
12. The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.
de Oliveira JM; Zurro NB; Coelho AVC; Caraciolo MP; de Alexandre RB; Cervato MC; Minillo RM; de Vasconcelos Carvalho Neto G; Grivicich I; Oliveira JB
Eur J Hum Genet; 2022 Jul; 30(7):818-823. PubMed ID: 35534704
[TBL] [Abstract] [Full Text] [Related]
13. Association of Pathogenic Variants in Hereditary cancer Genes With Multiple Diseases.
Zeng C; Bastarache LA; Tao R; Venner E; Hebbring S; Andujar JD; Bland ST; Crosslin DR; Pratap S; Cooley A; Pacheco JA; Christensen KD; Perez E; Zawatsky CLB; Witkowski L; Zouk H; Weng C; Leppig KA; Sleiman PMA; Hakonarson H; Williams MS; Luo Y; Jarvik GP; Green RC; Chung WK; Gharavi AG; Lennon NJ; Rehm HL; Gibbs RA; Peterson JF; Roden DM; Wiesner GL; Denny JC
JAMA Oncol; 2022 Jun; 8(6):835-844. PubMed ID: 35446370
[TBL] [Abstract] [Full Text] [Related]
14. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous ovarian Carcinoma.
Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
[TBL] [Abstract] [Full Text] [Related]
15. mutyh-associated tumor syndrome: The other face of MAP.
Magrin L; Fanale D; Brando C; Corsini LR; Randazzo U; Di Piazza M; Gurrera V; Pedone E; Bazan Russo TD; Vieni S; Pantuso G; Russo A; Bazan V
Oncogene; 2022 Apr; 41(18):2531-2539. PubMed ID: 35422474
[TBL] [Abstract] [Full Text] [Related]
16. Hereditary breast cancer and fertility preservation outcomes.
Arab S; Tulandi T; Buckett W
J Assist Reprod Genet; 2022 May; 39(5):1163-1168. PubMed ID: 35403930
[TBL] [Abstract] [Full Text] [Related]
17. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
Sahin I; Saat H
Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
[No Abstract] [Full Text] [Related]
18. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
[TBL] [Abstract] [Full Text] [Related]
19. Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With ovarian cancer: A Review.
Acs M; Piso P; Prader S
Anticancer Res; 2022 Jan; 42(1):13-24. PubMed ID: 34969704
[TBL] [Abstract] [Full Text] [Related]
20. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V
ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384
[TBL] [Abstract] [Full Text] [Related]
[Next]
